Malaria vaccine shows promise

Article Abstract:

The largest malaria vaccine efficacy trial conducted in Africa has proved that a candidate vaccine is safe in children aged 1 to 4 years and can protect a significant proportion of them against uncomplicated malaria, infection, and severe forms of the disease for at least 6 months. The research revealed that children who received 3 doses of the vaccine were 30 percent less likely to develop at least one episode of clinical malaria compared with children given a control vaccine.

Product information, Africa, Testing, Children, Drug therapy, Child health, Malaria, Malaria vaccine, Malaria vaccines

---

Reports help identify and manage autism

Article Abstract:

The importance of screening children between the ages of 18 to 24 months for autism related disorders is presented.

United States, Care and treatment, Evaluation, Reports, Diagnosis, Autism, Medical screening, Health screening, American Academy of Pediatrics

---

Similar abstracts:

• Abstracts: Marburg vaccine shows promise. Officials halt NSAID prevention trails. Malaria susceptibility heightened for some
• Abstracts: Age range widens for pertussis vaccine: Boosters advised for adolescents and adults. New vaccine should ease meningitis fears
• Abstracts: Advances in the treatment of prostate cancer. Molecular imaging in the development of cancer therapeutics. Advances in radiation oncology
• Abstracts: Is racism a problem in nursing? Health department policy may be worsening race inequalities. Report critical of lack of planning for nursing cover
• Abstracts: Increased role for nurses in provision of skin cancer care. Guidelines on the management of patients with hypertension

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.